WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013148871) ENGINEERED POLYPEPTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/148871    International Application No.:    PCT/US2013/034152
Publication Date: 03.10.2013 International Filing Date: 27.03.2013
IPC:
C07K 19/00 (2006.01), C12N 15/62 (2006.01), C12N 15/63 (2006.01), A61K 38/22 (2006.01), A61P 3/00 (2006.01)
Applicants: AMYLIN PHARMACEUTICALS, LLC [US/US]; 9360 Towne Center Drive San Diego, California 92121 (US).
ASTRAZENECA PHARMACEUTICALS LP [US/US]; 1800 Concord Pike Wilmington, Delaware 19897 (US).
ROTH, Jonathan David [US/US]; (US) (US only).
GHOSH, Soumitra S. [US/US]; (US) (US only)
Inventors: ROTH, Jonathan David; (US).
GHOSH, Soumitra S.; (US)
Agent: KOERBER, Steven C.; KILPATRICK TOWNSEND & STOCKTON LLP Two Embarcadero Center San Francisco, California 94111 (US)
Priority Data:
61/616,906 28.03.2012 US
Title (EN) ENGINEERED POLYPEPTIDES
(FR) POLYPEPTIDES GÉNÉTIQUEMENT MODIFIÉS
Abstract: front page image
(EN)Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens. The compounds are engineered polypeptides which incorporate an exendin domain in combination with a humanized chimeric seal leptin. Also provided are pharmaceutical compositions and methods of treatment for diseases including diabetes, overweight, obesity, Alzheimer's disease, short bowel syndrome, fatty liver disease, dyslipidemia, coronary artery disease, stroke, hyperlipidemia, NASH or Parkinson's disease.
(FR)L'invention concerne des composés présentant, entre autres, une bonne durée d'action, une puissance élevée et/ou des régimes de dosage pratiques. Ces composés sont des polypeptides génétiquement modifiés qui incorporent un domaine de l'exendine en combinaison avec une leptine chimère humanisée issue de la graisse de phoque. L'invention concerne également des compositions pharmaceutiques et des méthodes de traitement de maladies telles que le diabète, la surcharge pondérale, l'obésité, la maladie d'Alzheimer, le syndrome de l'intestin court, la stéatose hépatique, la dyslipidémie, la coronaropathie, l'accident vasculaire cérébral, l'hyperlipidémie, la stéatohépatite non alcoolique (NASH) ou la maladie de Parkinson.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)